Free Trial

Forte Biosciences (FBRX) Competitors

Forte Biosciences logo
$7.52 +0.41 (+5.77%)
Closing price 05/22/2025 03:59 PM Eastern
Extended Trading
$7.58 +0.07 (+0.86%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FBRX vs. KOD, TNXP, CRDF, SOPH, VYGR, YMAB, CRGX, ADCT, SCPH, and NBTX

Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Kodiak Sciences (KOD), Tonix Pharmaceuticals (TNXP), Cardiff Oncology (CRDF), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), CARGO Therapeutics (CRGX), ADC Therapeutics (ADCT), scPharmaceuticals (SCPH), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.

Forte Biosciences vs.

Kodiak Sciences (NASDAQ:KOD) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.

Forte Biosciences received 12 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 60.78% of users gave Forte Biosciences an outperform vote while only 26.76% of users gave Kodiak Sciences an outperform vote.

CompanyUnderperformOutperform
Kodiak SciencesOutperform Votes
19
26.76%
Underperform Votes
52
73.24%
Forte BiosciencesOutperform Votes
31
60.78%
Underperform Votes
20
39.22%

Kodiak Sciences' return on equity of -84.52% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -84.52% -45.40%
Forte Biosciences N/A -151.43%-118.92%

Kodiak Sciences has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500.

In the previous week, Kodiak Sciences had 5 more articles in the media than Forte Biosciences. MarketBeat recorded 8 mentions for Kodiak Sciences and 3 mentions for Forte Biosciences. Kodiak Sciences' average media sentiment score of 0.35 beat Forte Biosciences' score of 0.08 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Forte Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kodiak Sciences is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$260.49M-$3.63-0.98
Forte BiosciencesN/AN/A-$31.48M-$16.29-0.46

Kodiak Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 153.52%. Forte Biosciences has a consensus target price of $32.50, suggesting a potential upside of 332.18%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Forte Biosciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Forte Biosciences beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBRX vs. The Competition

MetricForte BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$49.50M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.10%
P/E Ratio-0.469.0626.7719.70
Price / SalesN/A259.83393.27122.35
Price / CashN/A65.8538.2534.62
Price / Book0.316.456.774.50
Net Income-$31.48M$143.98M$3.23B$248.22M
7 Day Performance-4.20%0.38%0.43%-0.80%
1 Month Performance24.30%2.14%9.07%11.52%
1 Year PerformanceN/A-0.33%18.57%8.99%

Forte Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBRX
Forte Biosciences
2.6161 of 5 stars
$7.52
+5.8%
$32.50
+332.2%
+31,233.3%$49.50MN/A-0.465Analyst Downgrade
KOD
Kodiak Sciences
3.6866 of 5 stars
$3.71
+6.0%
$9.00
+142.6%
+8.9%$195.75MN/A-1.0290Analyst Revision
TNXP
Tonix Pharmaceuticals
3.4793 of 5 stars
$26.60
-5.0%
$585.00
+2,099.2%
-95.7%$194.85M$10.04M-0.0150Analyst Upgrade
Gap Up
High Trading Volume
CRDF
Cardiff Oncology
1.6949 of 5 stars
$2.91
+3.6%
$12.00
+312.4%
-16.8%$193.59M$587,000.00-3.1020Positive News
SOPH
SOPHiA GENETICS
1.7761 of 5 stars
$2.86
-3.4%
$6.80
+137.8%
-38.5%$190.73M$67.17M-2.62520
VYGR
Voyager Therapeutics
4.665 of 5 stars
$3.43
+3.9%
$13.39
+290.4%
-64.0%$189.80M$66.96M4.83100
YMAB
Y-mAbs Therapeutics
3.4392 of 5 stars
$4.17
+1.7%
$16.60
+298.1%
-67.9%$188.83M$87.69M-7.72150Analyst Revision
CRGX
CARGO Therapeutics
2.1717 of 5 stars
$4.09
-0.7%
$15.00
+266.7%
-80.5%$188.59MN/A-0.96116Gap Up
ADCT
ADC Therapeutics
2.6737 of 5 stars
$2.34
+23.8%
$7.75
+231.2%
-39.8%$187.45M$70.84M-0.98310High Trading Volume
SCPH
scPharmaceuticals
4.0981 of 5 stars
$3.52
+9.3%
$14.00
+297.7%
-0.8%$185.83M$41.98M-1.8530High Trading Volume
NBTX
Nanobiotix
1.6814 of 5 stars
$3.94
+2.1%
$8.00
+103.0%
-39.7%$185.70M$-11,609,000.000.00100Gap Up

Related Companies and Tools


This page (NASDAQ:FBRX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners